Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2011

Martinelli P, Bonetti P, Sironi C, Pruneri G, Fumagalli C, Raviele PR, et al. The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. Blood. 2011;117(24):6617-26.

Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnström J, Sevvana M, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A. 2011;108(23):9613-8.

Ross AE, Emadi A, Marchionni L, Hurley PJ, Simons BW, Schaeffer EM, et al. Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity. BJU Int. 2011;108(3):447-54.

Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov. 2011;1(2):158-69.

Serur D, Saal S, Wang J, Sullivan J, Bologa R, Hartono C, et al. Deceased-donor kidney transplantation: improvement in long-term survival. Nephrol Dial Transplant. 2011;26(1):317-24.

McKnight R, Cohen C, Siddiqui MT. Fascin stain as a potential marker of invasiveness in carcinomas of the urinary bladder: a retrospective study with biopsy and cytology correlation. Diagn Cytopathol. 2011;39(9):635-40.

Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin P-, et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res. 2011;21(1):56-67.

Cooper J, Li W, You L, Schiavon G, Pepe-Caprio A, Zhou L, et al. Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression. Sci Signal. 2011;4(188):pt6.

Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 2011;1(2):144-57.

Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011;117(2):336-42.